Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Oct:289:173-175.
doi: 10.1016/j.atherosclerosis.2019.07.021. Epub 2019 Aug 6.

Statins and Lp(a): The plot thickens

Byambaa Enkhmaa  1 , Lars Berglund  2
Affiliations
Editorial

Statins and Lp(a): The plot thickens

Byambaa Enkhmaa et al. Atherosclerosis. 2019 Oct.
No abstract available

Keywords: Cardiovascular risk; Cholesterol; Drugs; Lipids; Lipoproteins.

PubMed Disclaimer

Conflict of interest statement

Disclosure of potential conflict of interest

The authors have nothing to disclose.

Figures

Figure 1.
Figure 1.. Statins versus PCSK9 inhibitors: Effects on LDL-C and Lp(a)
Both statins and PCSK9 inhibitors reduce LDL-C levels through mechanisms involving LDL receptor upregulation. In contrast, while PCSK9 inhibitors reduce Lp(a) levels, statins may increase Lp(a) levels. PCSK9-induced Lp(a) reduction maybe facilitated by markedly reduced competition from LDL-C for binding to LDL receptor and/or reduced production of apo(a) among patients taking PCSK9 inhibitors. On the other hand, increased production of apo(a), primarily of small sizes, may contribute to statin-induced Lp(a) elevation.
See this image and copyright information in PMC

Comment on

References

    1. Kuklina EV, Carroll MD, Shaw KM and Hirsch R, Trends in high LDL cholesterol, cholesterol-lowering medication use, and dietary saturated-fat intake: United States, 1976–2010. NCHS data brief 2013: 1–8. - PMC - PubMed
    1. Cheesman EJ, Sharp RJ, Zlot CH, Liu CY, Taylor S, Marcovina SM, et al., An analysis of the interaction between mouse apolipoprotein B100 and apolipoprotein(a). J Biol Chem 2000; 275: 28195–200. - PubMed
    1. Reyhana Yahya KB, Verhoeven Adrie, Bos Sven, van der Zee Leonie, Touw A, Erhart Gertraud, Kronenberg Florian, Timman Reinier, Sijbrands Eric, van Lennep Jeanine Roeters, Mulder Monique, Statin treatment increases lipoprotein(a) levels in subjects with low molecular weight polipoprotein(a) phenotype. Atherosclerosis 2019; In press. - PubMed
    1. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS and Breslow JL, HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 1989; 80: 1313–9. - PubMed
    1. Hunninghake DB, Stein EA and Mellies MJ, Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein(a), J Clin Pharmacol 1993; 33: 574–80. - PubMed

Substances